Results OlympiA trial

Daughters kissing their mother, family spending time together.

Dit bericht delen

Olaparib (Lynparza) in the adjuvant treatment of patients with germline BRCA1/2 mutations and high-risk early breast cancer reduced the risk of cancer recurrence by 42% in OlympiA Phase III trial

Results from the OlympiA Phase III trial showed olaparib (Lynparza) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. Upon review of the planned interim analysis in February 2021, the IDMC concluded that the trial had crossed the superiority boundary for its primary endpoint and recommended for the OlympiA trial to move early to primary analysis and reporting.

Results of this analysis will be presented during the plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract LBA#1). The results are being made available by ASCO on 3rd June and simultaneously published in The New England Journal of Medicine prior to their presentation in the plenary session.

An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020, and BRCA1 en BRCA2 mutations are found in approximately 5% of breast cancer patients.1,2

In the overall trial population of patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, results showed olaparib (Lynparza) reduced the risk of invasive breast cancer recurrences, second cancers or death by 42% (based on a hazard ratio [HR] of 0.58; 99.5% confidence interval [CI] 0.41-0.82; p<0.0001). At three years, 85.9% of patients treated with olaparib (Lynparza) remained alive and free of invasive breast cancer and second cancers versus 77.1% on placebo.

Olaparib (Lynparza) also demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of distant disease-free survival (DDFS) in the overall trial population. Olaparib (Lynparza) reduced the risk of distant disease recurrence or death by 43% (based on an HR of 0.57; 99.5% CI 0.39-0.83; p<0.0001). At the time of this initial data cut-off, fewer deaths had occurred in patients receiving olaparib (Lynparza), but the difference in overall survival (OS) did not reach statistical significance. The trial will continue to assess OS as a secondary endpoint. 

OlympiA Steering Committee Chair Andrew Tutt, Professor of Oncology at The Institute of Cancer Research, London, and King’s College London, said: “We are thrilled that our global academic and industry partnership has been able to help identify a possible new treatment for women with early-stage breast cancer who have mutations in their BRCA1 or BRCA2 genes. Olaparib has the potential to be used as a follow-on to all the standard initial breast cancer treatments to reduce the rate of life-threatening recurrence and cancer spread for many patients identified through genetic testing to have mutations in these genes.”

“Women with early-stage breast cancer who have inherited BRCA mutations are typically diagnosed at a younger age. Up to now, there has been no treatment that specifically targets these mutations to reduce the risk of recurrence beyond the standard treatments available for early breast cancer. This major international study coordinated by the Breast International Group shows that giving olaparib for a year after completion of chemotherapy to patients with BRCA1 and 2 mutations increases the chances that they will remain free of invasive or metastatic cancer. These results reinforce how collaborative cancer research deepens our understanding of treating familial cancers and shows the value of testing for these mutations in patients with early breast cancer.”

Charles Geyer, OlympiA Steering Committee co-Chair, Professor and Deputy Director of the Houston Methodist Cancer Center, said: “OlympiA represents a remarkable and successful global collaboration between leading international academic breast cancer research groups, cancer genetics experts, the National Cancer Institute and pharmaceutical industry partners to evaluate the efficacy and safety of olaparib to address the unmet need for improved therapy for individuals with high risk, inherited BRCA mutation-associated early breast cancer.”

Judy Garber, OlympiA Steering Committee co-Chair, Professor and Chief, Division of Cancer Risk and Prevention, Dana-Farber Cancer Institute, said: “The results of OlympiA highlight the importance of inherited cancer genetic testing being widely available, as the results have become essential to modern oncology for targeted therapy decisions, now at breast cancer diagnosis as well as at presentation with metastatic disease.”

Sue Friedman, Executive Director, Facing Our Risk of Cancer Empowered (FORCE, a leading advocacy organisation for individuals and families facing hereditary cancer), and member of the OlympiA trial steering committee, said: “While we have made great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients’ minds. New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.”

The safety and tolerability profile of olaparib (Lynparza) in this trial was in line with that observed in prior clinical trials. The most common adverse events (AEs) were nausea (57%), fatigue (40%), anaemia (24%) and vomiting (22%). Grade 3 or higher AEs were anaemia (9%), neutropenia (5%), leukopenia (3%), fatigue (2%), and nausea (1%). Approximately 10% of patients treated with olaparib (Lynparza) discontinued treatment early due to AEs compared to approximately 4% with placebo treatment.

OlympiA is a global collaborative Phase III trial coordinated by the Breast International Group (BIG) worldwide, in partnership with NRG Oncology, the US National Cancer Institute (NCI), Frontier Science & Technology Research Foundation (FSTRF), AstraZeneca and MSD.3 The trial is sponsored by NRG Oncology in the US and by AstraZeneca outside the US. We make a special mention of Professor Bella Kaufman (Sheba Medical Center, Israel), one of the OlympiA Steering Committee co-Chairs, who tragically passed away recently, before the results of this trial to which she contributed so muc‎h could be shared publicly.

Olaparib (Lynparza) is approved in the US, Japan, and a number of other countries for gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy; in the EU, this includes locally advanced breast cancer.

Early breast cancer
Breast cancer is the most common cancer among women worldwide and an estimated 70% of all breast cancer is diagnosed at an early stage.4,5 Breast cancer is one of the most biologically diverse tumour types with various factors underlying its development and progression.6 The discovery of biomarkers in the development of breast cancer has greatly impacted scientific understanding of the disease and treatment of patients who develop the disease.7

OlympiA is a Phase III, double-blind, placebo-controlled, multicentre trial testing the efficacy and safety of olaparib (Lynparza)  tablets versus placebo as adjuvant treatment in patients with gBRCAm, high-risk, HER2-negative early breast cancer, who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. The primary endpoint of the trial is iDFS defined as time from randomisation to date of first loco-regional or distant recurrence, new cancer or death from any cause. Key secondary endpoints include OS and DDFS, which is defined as time from randomisation until documented evidence of first distant recurrence of breast cancer or death without distant recurrence.3

Download it here: OlympiA Press Release 2021

For further information and/or interview requests, please contact:

voor BIG te waarborgen
Oriana Spagnolo
Communications Manager
Tel: +32 479 814831

Richard D. Gelber
Tel: +1 617 835 9537

NRG Oncology
Michelle Shepard
NRG Oncology – Pittsburgh Operations
Media & Communications Specialist
Nova Tower 2 / Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212 
Tel: (P) +1 412-339-5347


1. World Health Organization. Estimated number of cases in 2020, worldwide, both sexes, all ages. Available at: Accessed May 2021.

2. Mitri Z, et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemother Res Pract. 2012;743193.

3. Olaparib as Adjuvant Treatment in Patients with Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). Available at Accessed May 2021.

4. Breast Cancer School. Will I survive breast cancer? Available at: Accessed May 2021.

5. Bertozzi S, et al. Biomarkers in Breast Cancer. Intechopen. 2018.

6. Yersal O, and Barutca S. Biological Subtypes of Breast Cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-424.

7. Rivenbark A, et al. Molecular and Cellular Heterogeneity in Breast Cancer: Challenges for Personalized Medicine. Am J Pathol. 2013;183(4):1113-1124

8. Roy R, et al. BRCA1 and BRCA2: Different Roles in a Common Pathway of Genome Protection. Nat Rev Cancer. 2021;12(1):68–78.

9. Wu J, et al. The Role of BRCA1 in DNA Damage Response. Protein Cell. 2010;1(2):117-11.

10. Gorodetska I, et al. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J Cancer. 2019;10(9):2109-2127.

11. Li H, et al. PARP Inhibitor Resistance: The Underlying Mechanisms and Clinical Implications. Mol Cancer. 2020;19:107.

Meer te ontdekken

BIG Research in Focus - Fighting breast cancer around the globe; Canada and the BIG-NABCG collaboration

The AURORA project in metastatic breast cancer

AURORA Europe and US are two of the most ambitious programmes ever carried out to improve understanding of metastatic breast cancer [1] and have been established through